대사 패널 검사 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측 : 분석물별, 질환별, 최종 용도별, 지역별, 경쟁별(2020-2030년)
Metabolic Panel Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Analytes, By Disease, By End Use (Laboratory, PoC, PoC ), By Region and Competition, 2020-2030F
상품코드:1763972
리서치사:TechSci Research
발행일:2025년 06월
페이지 정보:영문 184 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
대사 패널 검사 세계 시장 규모는 2024년에 124억 1,000만 달러로 평가되었으며, 2030년에는 215억 6,000만 달러에 달할 것으로 예측되며, 예측 기간 동안 CAGR 9.62%로 성장할 것으로 예측됩니다.
전 세계적으로 헬스케어 시스템이 조기 진단과 예방의료를 우선시함에 따라 시장은 꾸준히 성장하고 있습니다. 종합대사패널(CMP) 검사는 신장 및 간 기능, 혈당, 전해질 균형에 대한 정보를 제공하는 일상적인 진단 도구가 되었습니다. 당뇨병, 신장 질환, 간 기능 장애와 같은 대사성 질환의 유병률이 증가함에 따라 CMP 검사는 임상 진단에 필수적인 검사로 자리 잡았습니다. 또한, 인구 고령화와 일상적인 건강 모니터링의 중요성이 증가함에 따라 CMP 검사를 받는 환자층이 확대되고 있으며, CMP 검사는 현재 입원 및 외래 환자에서 건강 검진의 일환으로 정기적으로 시행되고 있습니다. 검사실 자동화 및 디지털 데이터 통합과 같은 기술 발전으로 검사의 효율성과 정확성이 향상되고 있습니다. 맞춤형 의료 및 현장 검사 장비의 인기가 높아지고 있으며, 특히 응급 의료 및 원격지에서는 이러한 진단이 더욱 친숙해져 전체 시장 성장에 기여하고 있습니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
124억 1,000만 달러
시장 규모 : 2030년
215억 6,000만 달러
CAGR : 2025-2030년
9.62%
급성장 부문
당뇨병
최대 시장
북미
시장 촉진요인
만성질환 및 대사성 질환의 유병률 증가
주요 시장 과제
고가의 첨단 진단 장비
주요 시장 동향
개인화 및 예방적 건강관리로의 전환
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 세계의 대사 패널 검사 시장 전망
시장 규모 및 예측
금액별
시장 점유율과 예측
분석물별(K+, Na+, Cl-, CO2, 글루코스, BUN, 크레아티닌, Ca++, 알부민, 총 단백질, ALP, ALT, AST, 총 빌리루빈)
질환별(신장병, 간 병, 당뇨병, 기타)
최종 용도별(연구실, PoC, PoC(기기))
기업별(2024)
지역별
시장 맵
제6장 북미의 대사 패널 검사 시장 전망
시장 규모 및 예측
시장 점유율과 예측
북미 : 국가별 분석
미국
멕시코
캐나다
제7장 유럽의 대사 패널 검사 시장 전망
시장 규모 및 예측
시장 점유율과 예측
유럽 : 국가별 분석
프랑스
독일
영국
이탈리아
스페인
제8장 아시아태평양의 대사 패널 검사 시장 전망
시장 규모 및 예측
시장 점유율과 예측
아시아태평양 : 국가별 분석
중국
인도
한국
일본
호주
제9장 남미의 대사 패널 검사 시장 전망
시장 규모 및 예측
시장 점유율과 예측
남미 : 국가별 분석
브라질
아르헨티나
콜롬비아
제10장 중동 및 아프리카의 대사 패널 검사 시장 전망
시장 규모 및 예측
시장 점유율과 예측
중동 및 아프리카 : 국가별 분석
남아프리카공화국
사우디아라비아
아랍에미리트
제11장 시장 역학
성장 촉진요인
과제
제12장 시장 동향과 발전
인수합병
제품 출시
최근 동향
제13장 Porter's Five Forces 분석
업계내 경쟁
신규 참여의 가능성
공급업체의 능력
고객의 능력
대체품의 위협
제14장 경쟁 구도
Abbott Laboratories
Quest Diagnostics Incorporated
Laboratory Corporation of America Holdings Limited
Sonic Healthcare Limited
Unipath Specialty Laboratory Limited
SYNLAB International GmbH
ARUP Laboratories
Genoptix, Inc.
Nova Medical, Inc.
Mindray Medical International Limited
제15장 전략적 제안
제16장 조사 회사 소개 및 면책사항
ksm
영문 목차
영문목차
The Global Metabolic Panel Testing Market was valued at USD 12.41 billion in 2024 and is projected to reach USD 21.56 billion by 2030, growing at a CAGR of 9.62% during the forecast period. The market is expanding steadily as healthcare systems globally prioritize early diagnosis and preventive healthcare. Comprehensive Metabolic Panel (CMP) testing has become a routine diagnostic tool, offering insights into kidney and liver function, blood glucose, and electrolyte balance. The increasing prevalence of metabolic disorders such as diabetes, kidney disease, and liver dysfunction has made CMP tests vital in clinical diagnostics. Additionally, an aging population and the rising importance of routine health monitoring are enlarging the patient base for these tests. CMP testing is now a regular part of wellness checkups in both inpatient and outpatient settings. Technological advancements, including laboratory automation and digital data integration, are enhancing testing efficiency and accuracy. The rising popularity of personalized medicine and point-of-care testing devices, particularly in urgent care and remote areas, is making these diagnostics more accessible and contributing to overall market growth.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 12.41 Billion
Market Size 2030
USD 21.56 Billion
CAGR 2025-2030
9.62%
Fastest Growing Segment
Diabetes
Largest Market
North America
Key Market Drivers
Rising Prevalence of Chronic and Metabolic Disorders
The growing incidence of chronic and metabolic disorders is a major driver of the Global Metabolic Panel Testing Market. Noncommunicable diseases (NCDs) such as cardiovascular conditions, cancer, chronic respiratory diseases, and diabetes are now the leading causes of mortality globally. In 2021, NCDs were responsible for 75% of all deaths worldwide, with cardiovascular diseases causing 19 million deaths, cancers 10 million, chronic respiratory diseases 4 million, and diabetes over 2 million. Metabolic disorders like hypertension, high blood sugar, and elevated lipid levels are critical risk factors for these conditions. A global meta-analysis involving 28 million individuals found that the prevalence of metabolic syndrome ranges from 12.5% to 31.4%, with higher rates in the Eastern Mediterranean and the Americas. Many of these conditions remain undiagnosed until complications arise, highlighting the need for regular metabolic screening through CMP tests for early detection and preventive intervention.
Key Market Challenges
High Cost of Advanced Diagnostic Equipment
The cost associated with acquiring and operating advanced diagnostic equipment remains a key challenge in the Global Metabolic Panel Testing Market. Accurate CMP testing relies on sophisticated analyzers capable of evaluating multiple biomarkers, including glucose levels, enzymes, and electrolytes. These instruments involve substantial capital investment and require ongoing expenditure on maintenance and consumables. For smaller or resource-limited healthcare facilities, especially in developing regions, such expenses can be prohibitive. Smaller diagnostic laboratories may be unable to justify or afford the cost, leading to limited test offerings or dependence on outdated systems with lower accuracy and efficiency. This creates disparities in access to reliable diagnostics across different regions and facility types, posing a challenge to universal healthcare goals.
Key Market Trends
Shift Toward Personalized and Preventive Healthcare
A prominent trend influencing the Global Metabolic Panel Testing Market is the transition toward personalized and preventive healthcare. As healthcare providers increasingly focus on early detection and tailored treatment strategies, CMP testing plays an essential role in identifying metabolic imbalances before clinical symptoms emerge. The ability to detect early signs of conditions such as diabetes and hypertension allows for customized treatment planning, enhancing patient care outcomes. Advances in genomics are further supporting this shift, as genetic profiling is combined with CMP results to develop individualized health management approaches. This integration is fostering a proactive model of care, with the emphasis shifting from disease treatment to early intervention and disease prevention.
Key Market Players
Abbott Laboratories
Quest Diagnostics Incorporated
Laboratory Corporation of America Holdings Limited
Sonic Healthcare Limited
Unipath Specialty Laboratory Limited
SYNLAB International GmbH
ARUP Laboratories
Genoptix, Inc.
Nova Medical, Inc.
Mindray Medical International Limited
Report Scope:
In this report, the Global Metabolic Panel Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Metabolic Panel Testing Market, By Analytes:
K+
Na+
Cl-
CO2
Glucose
BUN
Creatinine
Ca++
Albumin
Total protein
ALP
ALT
AST
Total bilirubin
Metabolic Panel Testing Market, By Disease:
Kidney Disease
Liver Disease
Diabetes
Others
Metabolic Panel Testing Market, By End Use:
Laboratory
PoC
PoC (Instruments)
Metabolic Panel Testing Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Metabolic Panel Testing Market.
Available Customizations:
Global Metabolic Panel Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends
4. Voice of Customer
5. Global Metabolic Panel Testing Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Analytes (K+, Na+, Cl-, CO2, Glucose, BUN, Creatinine, Ca++, Albumin, Total protein, ALP, ALT, AST, Total bilirubin)
5.2.2. By Disease (Kidney Disease, Liver Disease, Diabetes, Others)
5.2.3. By End Use (Laboratory, PoC, PoC (Instruments))
5.2.4. By Company (2024)
5.2.5. By Region
5.3. Market Map
6. North America Metabolic Panel Testing Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Analytes
6.2.2. By Disease
6.2.3. By End Use
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Metabolic Panel Testing Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Analytes
6.3.1.2.2. By Disease
6.3.1.2.3. By End Use
6.3.2. Mexico Metabolic Panel Testing Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Analytes
6.3.2.2.2. By Disease
6.3.2.2.3. By End Use
6.3.3. Canada Metabolic Panel Testing Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Analytes
6.3.3.2.2. By Disease
6.3.3.2.3. By End Use
7. Europe Metabolic Panel Testing Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Analytes
7.2.2. By Disease
7.2.3. By End Use
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. France Metabolic Panel Testing Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Analytes
7.3.1.2.2. By Disease
7.3.1.2.3. By End Use
7.3.2. Germany Metabolic Panel Testing Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Analytes
7.3.2.2.2. By Disease
7.3.2.2.3. By End Use
7.3.3. United Kingdom Metabolic Panel Testing Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Analytes
7.3.3.2.2. By Disease
7.3.3.2.3. By End Use
7.3.4. Italy Metabolic Panel Testing Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Analytes
7.3.4.2.2. By Disease
7.3.4.2.3. By End Use
7.3.5. Spain Metabolic Panel Testing Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Analytes
7.3.5.2.2. By Disease
7.3.5.2.3. By End Use
8. Asia-Pacific Metabolic Panel Testing Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Analytes
8.2.2. By Disease
8.2.3. By End Use
8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Metabolic Panel Testing Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Analytes
8.3.1.2.2. By Disease
8.3.1.2.3. By End Use
8.3.2. India Metabolic Panel Testing Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Analytes
8.3.2.2.2. By Disease
8.3.2.2.3. By End Use
8.3.3. South Korea Metabolic Panel Testing Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Analytes
8.3.3.2.2. By Disease
8.3.3.2.3. By End Use
8.3.4. Japan Metabolic Panel Testing Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Analytes
8.3.4.2.2. By Disease
8.3.4.2.3. By End Use
8.3.5. Australia Metabolic Panel Testing Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Analytes
8.3.5.2.2. By Disease
8.3.5.2.3. By End Use
9. South America Metabolic Panel Testing Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Analytes
9.2.2. By Disease
9.2.3. By End Use
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Metabolic Panel Testing Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Analytes
9.3.1.2.2. By Disease
9.3.1.2.3. By End Use
9.3.2. Argentina Metabolic Panel Testing Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Analytes
9.3.2.2.2. By Disease
9.3.2.2.3. By End Use
9.3.3. Colombia Metabolic Panel Testing Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Analytes
9.3.3.2.2. By Disease
9.3.3.2.3. By End Use
10. Middle East and Africa Metabolic Panel Testing Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Analytes
10.2.2. By Disease
10.2.3. By End Use
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Metabolic Panel Testing Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Analytes
10.3.1.2.2. By Disease
10.3.1.2.3. By End Use
10.3.2. Saudi Arabia Metabolic Panel Testing Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Analytes
10.3.2.2.2. By Disease
10.3.2.2.3. By End Use
10.3.3. UAE Metabolic Panel Testing Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Analytes
10.3.3.2.2. By Disease
10.3.3.2.3. By End Use
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Porters Five Forces Analysis
13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Products
14. Competitive Landscape
14.1. Abbott Laboratories
14.1.1. Business Overview
14.1.2. Company Snapshot
14.1.3. Products & Services
14.1.4. Financials (As Reported)
14.1.5. Recent Developments
14.1.6. Key Personnel Details
14.1.7. SWOT Analysis
14.2. Quest Diagnostics Incorporated
14.3. Laboratory Corporation of America Holdings Limited
